Drugging RAS: Know the enemy
Open accessThe DOI matches its Crossref record; 50 of the 51 references it cites were found in a registry or an index.
Abstract
The three RAS oncogenes make up the most frequently mutated gene family in human cancer. The well-validated role of mutationally activated RAS genes in driving cancer development and growth has stimulated comprehensive efforts to develop therapeutic strategies to block mutant RAS function for cancer treatment. Disappointingly, despite more than three decades of research effort, clinically effective anti-RAS therapies have remained elusive, prompting a perception that RAS may be undruggable. However, with a greater appreciation of the complexities of RAS that thwarted past efforts, and armed with new technologies and directions, the field is experiencing renewed excitement that mutant RAS may finally be conquered. Here we summarize where these efforts stand.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“KRAS is the dominant oncogene in PDAC and is altered in more than 90% of tumors, with G12D, G12V, and G12R substitutions being most frequently observed (3, 4).”
From Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer (2024) · cites this paper as [3]
In the citing paper
“KRAS is the most frequently mutated oncogene, accounting for approximately 85% of all RAS mutations in 20–25% of all cancers [8–10].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [9]
In the citing paper
“It is difficult to achieve effective competition like protein kinase inhibitors [18, 19].”
From Targeting KRAS mutant cancers: from druggable therapy to drug resistance (2022) · cites this paper as [19]
In the citing paper
“On the one hand, the affinity of KRAS and GTP is at the pM level, while the concentration of GTP in cells is up to 0.5 μM.”
From Targeting KRAS mutant cancers: from druggable therapy to drug resistance (2022) · cites this paper as [19]
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition).
Klionsky, D. J., Abdelmohsen, K., Abe, A., Abedin, M. J., Abeliovich, H., Acevedo Arozena, A., Adachi, H., Adams, C. M., Adams, P. D., Adeli, K., et al. (2016) · Autophagy · doi:10.1080/15548627.2015.1100356 · Cited by 5,894
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism
Ying, H., Kimmelman, A. C., Lyssiotis, C. A., Hua, S., Chu, G. C., Fletcher-Sananikone, E., Locasale, J. W., Son, J., Zhang, H., Coloff, J. L., et al. (2012) · Cell · doi:10.1016/j.cell.2012.01.058 · Cited by 2,043
Drugging the undruggable RAS: Mission Possible?
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997
Self-citationGlutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway
Son, J., Lyssiotis, C. A., Ying, H., Wang, X., Hua, S., Ligorio, M., Perera, R. M., Ferrone, C. R., Mullarky, E., Shyh-Chang, N., et al. (2013) · Nature · doi:10.1038/nature12040 · Cited by 1,990
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikakos, P. I., Zhang, C., Bollag, G., Shokat, K. M., & Rosen, N. (2010) · Nature · doi:10.1038/nature08902 · Cited by 1,811
RAS oncogenes: weaving a tumorigenic web
Pylayeva-Gupta, Y., Grabocka, E., & Bar-Sagi, D. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3106 · Cited by 1,789
Pancreatic cancers require autophagy for tumor growth
Yang, S., Wang, X., Contino, G., Liesa, M., Sahin, E., Ying, H., Bause, A., Li, Y., Stommel, J. M., Dell'Antonio, G., et al. (2011) · Genes & Development · doi:10.1101/gad.2016111 · Cited by 1,498
Ras oncogenes: split personalities
Karnoub, A. E., & Weinberg, R. A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2438 · Cited by 1,467
Cited by
Items 201–300 of 406
The microdomain-organizing protein MPP1 is required for insulin-stimulated activation of H-Ras
Podkalicka, J., Biernatowska, A., Olszewska, P., Tabaczar, S., & Sikorski, A. F. (2018) · Oncotarget · doi:10.18632/oncotarget.24847 · Cited by 15
“Aberrant functions of Ras proteins have been known for many years to be correlated with many types of human cancer and a number of developmental disorders [3–5] what triggered many attempts to find Ras inhibitor as potential therapeutic compounds [6].”
BackgroundPatterning of Oncogenic Ras Clustering in Live Cells Using Vertically Aligned Nanostructure Arrays
Mu, H., Zeng, Y., Zhuang, Y., Gao, W., Zhou, Y., Rajalingam, K., & Zhao, W. (2022) · Nano Letters · doi:10.1021/acs.nanolett.1c03886 · Cited by 15
Facts and Hopes in Immunotherapy Strategies Targeting Antigens Derived from KRAS Mutations
Linette, G. P., Bear, A. S., & Carreno, B. M. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-1212 · Cited by 14
Synthetic Vulnerabilities in the KRAS Pathway
Román, M., Hwang, E. E., & Sweet-Cordero, A. (2022) · Cancers · doi:10.3390/cancers14122837 · Cited by 16
“Oncogenic mutations in RAS genes occur in approximately 30% of all human cancers (most commonly in lung, colon and pancreatic cancer), with KRAS mutations alone representing 85% of all RAS-driven cancers [5].”
BackgroundYuan, T., Liu, Y., Wu, R., Qian, M., Wang, W., Li, Y., Zhu, H., Wang, J., Ge, F., Zeng, C., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58923-y · Cited by 17
Pancreatic Tumorigenesis: Oncogenic KRAS and the Vulnerability of the Pancreas to Obesity
Luo, Y., Li, X., Ma, J., Abbruzzese, J. L., & Lu, W. (2021) · Cancers · doi:10.3390/cancers13040778 · Cited by 15
Recent Developments in Targeting RAS Downstream Effectors for RAS-Driven Cancer Therapy
Tatlı, Ö., & Doğanay, G. D. (2021) · Molecules · doi:10.3390/molecules26247561 · Cited by 16
“Oncogenic RAS signaling can be blocked indirectly by targeting the attachment of RAS to the inner plasma membrane or inhibiting RAS-dependent metabolic processes such as autophagy and macropinocytosis [16].”
BackgroundHou, Q., Jiang, W., Li, W., Huang, C., Yang, K., Chen, X., Huang, M., Shu, C., Luo, G., Sun, H., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00992 · Cited by 14
Ras-Dependent Cell Fate Decisions Are Reinforced by the RAP-1 Small GTPase in Caenorhabditis elegans
Rasmussen, N. R., Dickinson, D. J., & Reiner, D. J. (2018) · Genetics · doi:10.1534/genetics.118.301601 · Cited by 15
Role of KRAS in regulating normal human airway basal cell differentiation
Ogawa, F., Walters, M. S., Shafquat, A., O’Beirne, S. L., Kaner, R. J., Mezey, J. G., Zhang, H., Leopold, P. L., & Crystal, R. G. (2019) · Respiratory Research · doi:10.1186/s12931-019-1129-4 · Cited by 14
Endocrine-exocrine signaling drives obesity-associated pancreatic ductal adenocarcinomaPreprint
Chung, K. M., Singh, J., Lawres, L., Dorans, K. J., Garcia, C. C., Burkhardt, D. B., Robbins, R., Bhutkar, A. J., CARDONE, R. L., Zhao, X., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/663583 · Cited by 14
Targeting KRAS Oncogene for Patients With Colorectal Cancer: A New Step Toward Precision Medicine
Şahin, İ. H., Saridogan, T., Ayasun, R., Syed, M. P., Gorantla, V. C., Malhotra, M. K., Thomas, R. A., Rhee, J. C., Zhang, J. Y., Hsu, D. J., et al. (2024) · JCO Oncology Practice · doi:10.1200/op.23.00787 · Cited by 14
Wang, M., Hong, Y., Feng, Q., Pan, X., Song, S., Cui, J., Lei, J., Fang, H., & Yang, J.-L. (2018) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2018.10.003 · Cited by 13
Shin, H., Braendle, C., Monahan, K. B., Kaplan, R. E. W., Zand, T. P., Mote, F. S., Craig, D. R., Peters, E., & Reiner, D. J. (2019) · PLoS Genetics · doi:10.1371/journal.pgen.1008056 · Cited by 14
Identification of lysine methylation in the core GTPase domain by GoMADScan
Yoshino, H., Yin, G., Kawaguchi, R. K., Popov, K. I., Temple, B. R. S., Sasaki, M., Kofuji, S., Wolfe, K., Kofuji, K., Okumura, K., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0219436 · Cited by 14
Ras functional proximity proteomics establishes mTORC2 as new direct ras effector
Kovalski, J. R., Shanderson, R. L., & Khavari, P. A. (2019) · Oncotarget · doi:10.18632/oncotarget.27025 · Cited by 13
“The complexity of Ras regulation and signaling, however, present considerable current challenges [3].”
BackgroundHanley, K. L., Liang, Y., Wang, G., Lin, X., Yang, M., Karin, M., Fu, W., & Feng, G. (2021) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-0479 · Cited by 16
Shishina, A. K., Kovrigina, E. A., Galiakhmetov, A. R., Rathore, R., & Kovrigin, E. L. (2017) · Biochemistry · doi:10.1021/acs.biochem.7b01181 · Cited by 13
Proximal Protein Interaction Landscape of RAS Paralogs
Béganton, B., Coyaud, É., Laurent, E. M. N., Mangé, A., Jacquemetton, J., Romancer, M. L., Raught, B., & Solassol, J. (2020) · Cancers · doi:10.3390/cancers12113326 · Cited by 14
RASopathies – what they reveal about RAS/MAPK signaling in skeletal muscle development
Rauen, K. A., & Tidyman, W. E. (2024) · Disease Models & Mechanisms · doi:10.1242/dmm.050609 · Cited by 14
“Variants in the canonical RAS genes ( HRAS , KRAS and NRAS ) often activate RAS signaling, resulting in the dysregulation of the cell cycle and many other vital cellular processes.”
BackgroundInfluentialLiu, D., Ertay, A., Hill, C. N., Zhou, Y., Li, J., Zou, Y., Qiu, H., Yuan, X., Ewing, R. M., Lü, X., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2415-2 · Cited by 13
Pancreatic adenocarcinoma: molecular drivers and the role of targeted therapy
Al-Share, B. A., Hammad, N., & Diab, M. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09948-w · Cited by 15
“Therefore, research on KRAS drug development focused on disruption of regulator/effector interaction and inhibition of downstream effectors such as PI3K/AKT and MAPK/ERK pathways, as well as membrane association, synthetic interaction, and metabolism [114].”
BackgroundWang, P., van der Hoeven, D., Ye, N., Chen, H., Liu, Z., Ma, X., Montufar‐Solis, D., Rehl, K. M., Cho, K., Thapa, S., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113381 · Cited by 12
Endogenous Gastrin Collaborates With Mutant KRAS in Pancreatic Carcinogenesis
Nadella, S., Burks, J., Huber, M., Wang, J., Cao, H., Kallakury, B., Tucker, R. D., Boca, S. M., Jermusyk, A. A., Collins, I. J., et al. (2019) · Pancreas · doi:10.1097/mpa.0000000000001360 · Cited by 12
“The KRAS gene is the mostly highly mutated gene in pancreatic cancer,(73) and despite many years of effort, no successful antiRAS therapy has been developed, prompting the perception that RAS is undruggable.(74,75) New strategies are now being explored to perhaps target the downstream proteins or kinases activated by…”
BackgroundKovar, S. E., Fourman, C., Kinstedt, C., Williams, B., Morris, C., Cho, K., & Ketcha, D. M. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2020.127144 · Cited by 13
Yang, Y., Zhao, C.-J., Jin, Z.-F., Zheng, J., & Ma, L. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1120828 · Cited by 15
Med23 deficiency reprograms the tumor microenvironment to promote lung tumorigenesis
Fu, X., Liu, S., Cao, D., Li, C., Ji, H., & Wang, G. (2024) · British Journal of Cancer · doi:10.1038/s41416-023-02556-9 · Cited by 11
Wang, P., Pan, X., Feng, Q., Zou, H., Cui, J., He, Y., Luo, Y., & Yang, J.-L. (2020) · Immunotherapy · doi:10.2217/imt-2019-0222 · Cited by 11
Shapira, S., Boustanai, I., Kazanov, D., Shimon, M. B., Fokra, A., & Arber, N. (2021) · Oncogene · doi:10.1038/s41388-021-01792-8 · Cited by 14
Early-stage structure-based drug discovery for small GTPases by NMR spectroscopy
Yin, G., Lv, G., Zhang, J., Jiang, H., Lai, T., Yang, Y., Ren, Y., Wang, J., Yi, C., Chen, H., et al. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108110 · Cited by 11
Discovery of novel SOS1 inhibitors using machine learning
Duo, L., Chen, Y., Liu, Q., Ma, Z., Farjudian, A., Ho, W. Y., Low, S. S., Ren, J., Hirst, J. D., Xie, H. Q., et al. (2024) · RSC Medicinal Chemistry · doi:10.1039/d4md00063c · Cited by 12
Assessment of KRASG12C inhibitors for colorectal cancer
Piazza, G. A., Chandrasekaran, P., Maxuitenko, Y. Y., & Budhwani, K. I. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1412435 · Cited by 11
“Until recently, KRAS was considered undruggable as the protein apparently lacked deep pockets for small molecule binding, apart from the nucleotide binding domain (13).”
BackgroundGüngör, E. M., Altıntop, M. D., Sever, B., & Çiftçi, G. A. (2020) · Letters in Drug Design & Discovery · doi:10.2174/1570180817999200618163507 · Cited by 11
Patel, H. V., Johnson, M., Brea, R. J., Rudd, A. K., & Devaraj, N. K. (2020) · ACS Chemical Biology · doi:10.1021/acschembio.0c00222 · Cited by 11
Gastl, B., Klotz‐Noack, K., Klinger, B., Ispasanie, S., Salib, K. H. F., Zuber, J. A., Mamlouk, S., Bublitz, N., Blüthgen, N., Horst, D. A., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2704-9 · Cited by 11
EPHA2 feedback activation limits the response to PDEδ inhibition in KRAS-dependent cancer cells
Chen, Y., Lv, H., Shen, N., Wang, X., Tang, S., Xiong, B., Ding, J., Geng, M., & Huang, M. (2019) · Acta Pharmacologica Sinica · doi:10.1038/s41401-019-0268-y · Cited by 11
DNA Methylation Ageing Atlas Across 17 Human TissuesPreprint
Jacques, M., Seale, K., Voisin, S. A. C., Lysenko, A., Grolaux, R., Jones, B., Lamon, S., Levinger, I., Bauer, C., Sharples, A. P., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.07.21.665830 · Cited by 13
Gluing GAP to RAS Mutants: A New Approach to an Old Problem in Cancer Drug Development
Ranđelović, I., Nyíri, K., Koppány, G., Baranyi, M., Tóvári, J., Kigyós, A., Tímár, J., Vértessy, B. G., & Grolmusz, V. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052572 · Cited by 10
“…genes (or oncogenes) are known today [1] (cf. the Catalogue of Somatic Mutations In Cancer, https://cancer.sanger.ac.uk/cosmic, accessed on 16 February 2024); from these, numerous entries are connected to the RAS gene, whose mutations are found in approximately 25% of all human tumors [2,3].”
BackgroundOta, T. (2024) · Journal of Neuroendovascular Therapy · doi:10.5797/jnet.ra.2024-0008 · Cited by 10
Engineered depalmitoylases enable selective manipulation of protein localization and function
Jayaraman, S., Kochiss, A. L., Alcalay, T.-L., Morfin, P. J. D. R., & Johny, M. B. (2025) · Nature Communications · doi:10.1038/s41467-025-58908-x · Cited by 10
“Ras is the most frequently mutated gene family in cancers 49,64 .”
An Internally Controlled Quantitative Target Occupancy Assay for Covalent Inhibitors
Hansen, R., Firdaus, S. J., Li, S., Janes, M. R., Zhang, J., Liu, Y., & Zarrinkar, P. P. (2018) · Scientific Reports · doi:10.1038/s41598-018-32683-w · Cited by 10
Unraveling and targeting RAS-driven metabolic signaling for therapeutic gain
DeLiberty, J. M., Robb, R. N., Gates, C. E., & Bryant, K. L. (2022) · Advances in cancer research · doi:10.1016/bs.acr.2021.07.010 · Cited by 11
Nussbaum, D. P., Martz, C. A., Waters, A. M., Barrera, A., Liu, A., Rutter, J. C., Cerda-Smith, C. G., Stewart, A. E., Wu, C., Çakır, M., et al. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00615-9 · Cited by 10
“The RAS family of oncoproteins represents the most frequently mutated genes in humancancers 53,54 , and KRAS , inparticular, is altered in a subsetof the most common and deadly solid tumors 23 – 25 .”
Self-citationBinot, C., Sadoc, J.-F., & Chouard, C. H. (2018) · Heliyon · doi:10.1016/j.heliyon.2018.e00687 · Cited by 10
“2 and to relate 4 metabolic pathways: Phosphoinositides, Phosphatidylinositol 3 Kinase (PI3K)/Protein Kinase B (Akt)/Mammalian Target of Rapamycin (mTOR), [11, 14, 15, 16], Sterol Regulatory Element-Binding Protein (SREBP), Cleavage Activated Ptotein (SCAP), Insulin induced Gene (INSIG), Hydroxymethyl-glutaryl-coenzym…”
BackgroundRNF141 interacts with KRAS to promote colorectal cancer progression
Zhang, J., Jiang, X., Yin, J., Dou, S., Xie, X., Liu, T., Wang, Y., Wang, S., Zhou, X., Zhang, D., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01877-4 · Cited by 12
“It was previously reported that mono-ubiquitin modification of KRAS at different specific site generated different impacts on protein–protein interactions and KRAS activity in a nucleotide-independent or nucleotide-dependent manner [47–50], which accounted for the intricacy of KRAS and reiterative failure of anti-KRAS…”
BackgroundTargeting endogenous K-RAS for degradation through the affinity-directed protein missile systemPreprint
Röth, S., Macartney, T., Konopacka, A., Queisser, M. A., & Sapkota, G. P. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/805150 · Cited by 10
“However, these barriers and failure to directly target RAS have prompted researchers to explore targeting upstream regulators, or downstream effectors of RAS proteins (Cox et al., 2014; Kang et al., 2009; Leung et al., 2018; Papke and Der, 2017; Waldmann et al., 2004), as well as altering levels of RAS protein, for ex…”
BackgroundMeta-analysis of DNA methylation aging signatures in 17 human tissues
Jacques, M., Seale, K., Voisin, S. A. C., Lysenko, A., Grolaux, R., Jones-Freeman, B., Lamon, S., Abeysooriya, M., Levinger, I., Bauer, C., et al. (2026) · Nature Aging · doi:10.1038/s43587-026-01164-5 · Cited by 17
“Dysregulation of GTPases is linked to neurodegeneration, immunosenescence and senescence 7,35–37 .”
Wang, L., Zhang, H., Li, Y., & Li, L. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122437 · Cited by 11
Presence or Absence of Ras Dimerization Shows Distinct Kinetic Signature in Ras-Raf Interaction
Sarkar, S., & García, A. E. (2020) · Biophysical Journal · doi:10.1016/j.bpj.2020.03.004 · Cited by 9
Lee, W., Song, G., & Bae, H. (2023) · Antioxidants · doi:10.3390/antiox12020257 · Cited by 11
“of KRAS have focused on the indirect inhibition of KRAS by blocking downstream effectors, RAF-MEK-ERK and PI3K-AKT-mTOR signaling pathways [55].”
BackgroundPancreatic cancer: genetics, disease progression, therapeutic resistance and treatment strategies
Singh, K., Shishodia, G., & Koul, H. K. (2021) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2021.96 · Cited by 10
“%) adenocarcinomas [34] .”
MEK Inhibition Modulates Cytokine Response to Mediate Therapeutic Efficacy in Lung Cancer
Xie, M., Zheng, H., Madan-Lala, R., Dai, W., Gimbrone, N. T., Chen, Z., Kinose, F., Blackstone, S. A., Smalley, K. S. M., Cress, W. D., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0698 · Cited by 10
“A variety of approaches are being pursued to target the RAS pathway including the development of inhibitors that directly target RAS proteins (10).”
Interaction between RAS gene and lipid metabolism in cancer
Zhang, M., Pan, J., & Huang, P. (2021) · Journal of Zhejiang University (Medical Sciences) · doi:10.3724/zdxbyxb-2021-0054 · Cited by 9
Yu, J. X., Suh, J. M., Popova, K. D., Garcia, K., Joshi, T. V., Culbertson, B., Spinelli, J. B., Subramanyam, V., Lou, K., Charbonneau, T., et al. (2026) · Nature Cancer · doi:10.1038/s43018-026-01130-5 · Cited by 11
Zheng, Y., Li, J., Xu, D., Liu, L., Li, Y., Yi, J., Dong, J., Pang, D., & Tang, H. (2024) · Acta Biomaterialia · doi:10.1016/j.actbio.2024.06.046 · Cited by 9
Zhao, D.-R., Yang, J.-T., Liu, M.-T., Yang, L.-Q., & Sang, P. (2025) · RSC Advances · doi:10.1039/d4ra07924h · Cited by 11
Inhibition of K-Ras4B-plasma membrane association with a membrane microdomain-targeting peptide
Li, F.-Y., Zhang, Z., Voß, S., Wu, Y., Zhao, Y., Li, Y., & Chen, Y. (2019) · Chemical Science · doi:10.1039/c9sc04726c · Cited by 9
Assi, M., Pirlot, B., Stroobant, V., Thissen, J., & Jacquemin, P. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176361 · Cited by 8
“The above-mentioned finding suggests that KRAS is only partially active in the adult pancreas as it majorly expresses the unprenylated form; this form cannot reach the cell membrane and, thus, is not active [8].”
BackgroundDifferential Response and Resistance to KRAS-Targeted Therapy
Liu, Z., Lenz, H., Yu, J., & Zhang, L. (2025) · Molecular Carcinogenesis · doi:10.1002/mc.23908 · Cited by 7
Wang, L., Chen, X., Qu, R., Shao, S., Gong, L., Li, T., Jiang, S., Lu, Y., Ma, Y., Sun, Y. N., et al. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.218013 · Cited by 7
Wild-type RAS signaling is an essential therapeutic target in RAS -mutated cancers
Sealover, N. E., Finniff, B. A., Hughes, J. M., Sheffels, E., Lee, H., LaMorte, J. P., Gambhir, V., Beckley, Z., Linke, A. J., Wilkerson, M. D., et al. (2025) · Science Signaling · doi:10.1126/scisignal.adx5186 · Cited by 7
Shang, Y., Pang, M., Fu, S., Fei, W., Chen, B.-X., Zhang, Y., Wang, J., & Shen, T. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117391 · Cited by 8
RASpecting the oncogene: New pathways to therapeutic advances
Stout, M. C., & Campbell, P. M. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.10.022 · Cited by 7
Molecular Approach to Colorectal Carcinoma
Beech, C. M., & Hechtman, J. F. (2024) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2023.08.011 · Cited by 8
Liu, C., Zheng, S., Wang, S., Wang, X., Feng, X., Sun, N., & He, J. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211006949 · Cited by 8
Peptidomimetics designed to bind to RAS effector domain are promising cancer therapeutic compounds
Pallara, C., Cabot, D., Rivas, J., Brun, S., Seco, J., Abuasaker, B., Tarragó, T., Jaumot, M., Prades, R., & Agell, N. (2022) · Scientific Reports · doi:10.1038/s41598-022-19703-6 · Cited by 7
Efficacy and safety signals from early-phase studies of KRAS inhibition in pancreatic cancer
Tiede, K. O. M., Teixeira, M. F., Moura, M., Chiaini, O., Moura, F., Sonbol, M. B., Borad, M. J., Bekaii‐Saab, T., & Usón, P. L. S. (2026) · Scientific Reports · doi:10.1038/s41598-026-40757-3 · Cited by 7
Sequence-defined phosphoestamers for selective inhibition of the KRAS G12D /RAF1 interaction
Claringbold, B., Vance, S., Paul, A. R., Williamson, J., Garrett, M. D., & Serpell, C. J. (2024) · Chemical Science · doi:10.1039/d4sc07218a · Cited by 6
“13 The di ffi culty in drug discovery for RAS is that the only obvious pocket for a small molecule is occupied by GDP or GTP which are both strongly bound, 14 and present at high cellular concentrations, 15 making their replacement di ffi cult to envisage.”
Recent advances in targeted degradation in the RAS pathway
Ge, Z., Fan, Z., He, W., Zhou, G., Zhou, Y., Zheng, M., & Zhang, S. (2025) · Future Medicinal Chemistry · doi:10.1080/17568919.2025.2476387 · Cited by 7
Computational Approaches to Identify Genetic Interactions for Cancer Therapeutics
Benstead-Hume, G., Wooller, S. K., & Pearl, F. M. G. (2017) · Berichte aus der medizinischen Informatik und Bioinformatik/Journal of integrative bioinformatics · doi:10.1515/jib-2017-0027 · Cited by 7
“Improved screening through CRISPR-cas9-based techniques may provide further potential SDL interactors for mutant RAS genes in future studies [77].”
BackgroundYoon, S., Yang, H., Ryu, H.-M., Lee, E., Jo, Y., Seo, S., Kim, D., Lee, C. H., Kim, W., Jung, K. H., et al. (2021) · Cancer Research and Treatment · doi:10.4143/crt.2021.651 · Cited by 7
Liu, G., Jia, R., Deng, H., & Wang, T. (2025) · Discover Oncology · doi:10.1007/s12672-025-02975-5 · Cited by 5
Hosen, S. M. Z., Kumar, A. A., Xu, Z.-H., Mekapogu, A. R., Perera, C. J., Pang, T., Pirola, R. C., Wilson, J. S., Goldstein, D. S., Buckley, B. J., et al. (2025) · Gastroenterology · doi:10.1053/j.gastro.2025.07.021 · Cited by 6
Evaluation of a Novel Pan-RAS Inhibitor in 3D Bioprinted Tumor Models
de Nóbrega, D. F., Eiler, L. C., Ahirwar, P., Nallapu, S., Rawal, U. P., Crawford, C. L., Buchsbaum, D. J., Keeton, A. B., Maxuitenko, Y. Y., Chen, X., et al. (2025) · Cancers · doi:10.3390/cancers17182958 · Cited by 5
“However, KRAS was long considered undruggable [12] due to its high affinity for GTP/GDP and the lack of deep pockets for small molecule binding other than the nucleotide-binding domain [13].”
Kral, A. J., Jia, L., Sim, G., Wan, L., Ishigami, Y., & Krainer, A. R. (2025) · Molecular Cell · doi:10.1016/j.molcel.2025.12.004 · Cited by 9
IKKβ Kinase Promotes Stemness, Migration, and Invasion in KRAS-Driven Lung Adenocarcinoma Cells
Rodrigues, F. S., Miranda, V. S., Carneiro-Lobo, T., Scalabrini, L. C., Kruspig, B., Levantini, E., Murphy, D. J., & Bassères, D. S. D. S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165806 · Cited by 5
“On the other hand, targeting traditional downstream effectors of KRAS has only reached limited efficacy due to poor therapeutic windows coupled with paradoxical pathway activation by signalling loops [5].”
Discoveries in the redox regulation of KRAS
Kramer‐Drauberg, M., & Ambrogio, C. (2020) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2020.105901 · Cited by 6
Molecular Approach to Colorectal Carcinoma
Beech, C. M., & Hechtman, J. F. (2021) · Surgical pathology clinics · doi:10.1016/j.path.2021.05.007 · Cited by 6
Ren, Y., Wang, Y., Fang, L., Ma, M., Ge, L., Su, C., Xin, L., He, J., Yang, J., & Liu, X. (2022) · Cancer Medicine · doi:10.1002/cam4.5251 · Cited by 5
Alawawdeh, A., Piantadosi, C., Townsend, A. R., Karapetis, C. S., Padbury, R., Roy, A. C., Moore, J., Maddern, G., Roder, D., Smith, A., et al. (2022) · Targeted Oncology · doi:10.1007/s11523-021-00856-9 · Cited by 5
Luo, K., Song, Y., Guan, Z., Wang, H., Ye, J., Ran, S., Ou, S., Tao, Y., Gong, Z., Ma, T., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.899725 · Cited by 5
“Despite more than 3 decades of research efforts, there are still no effective inhibitors against KRAS for routine clinical practice, prompting the concept that RAS may be undruggable (Papke and Der, 2017).”
BackgroundTortajada-Genaro, L. A., Lázaro, A. M. P., Martorell, S., & Maquieira, Á. (2023) · Analytica Chimica Acta · doi:10.1016/j.aca.2023.341343 · Cited by 5
Targeting RAS – will GPR31 deliver us a new path forward?
Fehrenbacher, N., & Philips, M. R. (2017) · Molecular & Cellular Oncology · doi:10.1080/23723556.2017.1359228 · Cited by 5
“Thus, the search for drug targets in these processes has begun and inhibitors of cancer-relevant metabolic pathways are currently under preclinical and clinical investigation.(2)”
BackgroundTargeting the Architecture of Deregulated Protein Complexes in Cancer
Stefan, E., Troppmair, J., & Bister, K. (2017) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2017.07.001 · Cited by 7
DNA Methylation Ageing Atlas Across 17 Human TissuesPreprint
Eynon, N., Jacques, M., Seale, K., Voisin, S. A. C., Lysenko, A., Grolaux, R., Jones, B., Lamon, S., Levinger, I., Bauer, C., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-7184037/v1 · Cited by 6
The RAS Signaling Network and Cancer
Hibshman, P. S., & Der, C. J. (2024) · Springer eBooks · doi:10.1007/978-3-031-62945-7_17 · Cited by 4
Self-citationTargeting oncogenic K-RAS mutants with small-molecule degrader XMU-MP-9 through NEDD4-1
Zeng, T., Jiang, T., Zhang, B., Zhang, T., Dai, W., Yin, X., Li, Y., Yu, Z., Wu, C., Wu, Y., et al. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.07.031 · Cited by 7
Fragment-Based Drug Discovery for Developing Inhibitors of Protein-Protein Interactions
Xiong, B., Wang, Q., & Shen, J. (2018) · Springer eBooks · doi:10.1007/978-981-13-0773-7_6 · Cited by 5
Generation of Patient-Derived Colorectal Cancer Organoids for RAS Studies
Schumacher, D., Regan, J. L., Przybilla, D., & Schäfer, R. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1190-6_22 · Cited by 4
[Research Progress of Proteolysis Targeting Chimeria in NSCLC Therapy].
Jiang, L., Zhang, J., Hu, J., Qi, H., & Xu, H. Y. (2022) · PubMed Central · doi:10.3779/j.issn.1009-3419.2022.102.19 · Cited by 7
Franz, M., Mörchen, B., Degenhart, C., Gülden, D., Shkura, O., Wolters, D. A., Koch, U., Klebl, B., Stoll, R., Helfrich, I., et al. (2021) · ChemMedChem · doi:10.1002/cmdc.202100167 · Cited by 4
Ali, Y., Khan, A. A., Alanazi, A. M., Fatima, S., & Kozmon, S. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.132477 · Cited by 3
Seok, E., Son, M., Lee, S., Cheong, H.-T., & Lee, S. (2025) · Animals · doi:10.3390/ani15142100 · Cited by 4
“Conversely, Ras-GTP is hydrolyzed to Ras-GDP with the assistance of Ras-GTPase-activating protein (GAP) [17,22].”
Shen, T., Fei, W., Hu, Z., Pang, M., Ma, J., Zhou, T., & Shang, Y. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.109345 · Cited by 4
Kim, D. H., Lee, E. K., & Lee, S. (2025) · Physical Chemistry Chemical Physics · doi:10.1039/d5cp03384e · Cited by 3
Kehinde, S. A., Olajide, A. T., Akinpelu, O. J., & Ogunsanya, S. T. (2023) · Life Sciences Medicine and Biomedicine · doi:10.28916/lsmb.7.1.2023.113 · Cited by 3
Cregg, J., Edwards, A. V., Tomlinson, A. C. A., Gill, A. L., & Koltun, E. S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-21861-3.00011-5 · Cited by 3
Wang, W., Alley, A., Sun, N., Tadesse, M., Wang, X., & Zhang, R. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1663766 · Cited by 7
KRAS: Structure, function, and development of anticancer drugs
Parasrampuria, D. A., Yu, A., & Haddish‐Berhane, N. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818168-3.00013-9 · Cited by 6
KRAS Addiction Promotes Cancer Cell Adaptation in Harsh Microenvironment Through Macropinocytosis
Seguin, L. (2022) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-3-030-94004-1_10 · Cited by 3
Metadata
- Authors
- Papke, B., & Der, C. J.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Der, Channing J.
- Venue
- Science
- Published
- 2017-03-17
- Volume
- 355
- Issue
- 6330
- Pages
- 1158-1163
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2597182072
- Cited by
- 399
- References
- 51
- Citations by year
- 2026: 25 · 2025: 37 · 2024: 45 · 2023: 30 · 2022: 46 · 2021: 52 · 2020: 48 · 2019: 51 · 2018: 45 · 2017: 20
- FWCI
- 4.24
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- U.S. Department of Defense (W81XWH-15-1-0611)
- National Cancer Institute (CA042978, CA175747, CA199235, CA203657)
- Pancreatic Cancer Action Network
- Lustgarten Foundation
- Deutsche Forschungsgemeinschaft (PA 3051/1-1)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- oncogenic Ras, anticancer drug development, Ras signaling
- MeSH terms
- Antineoplastic Agents, Cell Membrane, Enzyme Inhibitors, Humans, Mutation, Neoplasms, Drug Design, ras Proteins, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.